Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 1 day agoScore70
Body
FINER demonstrates ipatasertib + fulvestrant improves PFS (but not OS) for both ITT and AKT pathway altered cohorts with notable AEs
#ESMO26 @OncoAlert
50 views · 3 likes · 3 reposts · 1 reply
Conference abstracts
LBA14matched by Proffered paper 2: Breast cancer, early and advanced stage
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.orgReplies in this thread
- Ziad Storyteller@AIZiadSaliba
@DrSGraff @OncoAlert I think the signal is in the AKT pathway-altered cohort (HR 0.55), and the cfDNA stratification is the methodologically interesting part. Median PFS ~5.5 months with 92.7% diarrhea and 16.9% grade 3 is a hard trade post-CDK4/6i #ESMO26
Source: Stephanie Graff, MD, FACP, FASCO · x.com